SCHEMBL3473727

SCHEMBL3473727

CN(C(=O)Cn1c(=O)cnn(-c2ccc(Cl)c(C(=O)NCC3(O)CCCCCC3)c2)c1=O)C1CC1

nearest known ligand 0.75

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 20/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3476183 0.92 P2RX7 (0.80) P2RX7
SCHEMBL5957131 0.88 P2RX7 (0.59) P2RX7
SCHEMBL3475121 0.88 P2RX7 (0.84) P2RX7
SCHEMBL3475799 0.87 P2RX7 (0.82) P2RX7
SCHEMBL3474449 0.87 P2RX7 (0.82) P2RX7
SCHEMBL3476059 0.87 P2RX7 (0.82) P2RX7
SCHEMBL3473731 0.87 P2RX7 (0.73) P2RX7
SCHEMBL3474831 0.86 P2RX7 (0.81) P2RX7
SCHEMBL3474422 0.85 P2RX7 (0.82) P2RX7
SCHEMBL3474344 0.85 P2RX7 (0.80) P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7671053-B2 Benzamide inhibitors of the P2X7 receptor PFIZER, INC. (US) 2010-03-02 US disclosed
US-20090042886-A1 Benzamide Inhibitors of the P2X7 Receptor PFIZER, INC. (US) 2009-02-12 US disclosed
US-7407956-B2 Benzamide inhibitors of the P2X7 receptor PFIZER, INC. (US) 2008-08-05 US disclosed
US-20070281939-A1 Benzamide Inhibitors of The P2X7 Receptor PFIZER INC. 2007-12-06 US disclosed
US-7176202-B2 Benzamide inhibitors of the P2X7 receptor PFIZER INC. (US) 2007-02-13 US disclosed
US-20060040939-A1 Benzamide inhibitors of the P2X, receptor DOMBROSKI MARK A 2006-02-23 US disclosed
US-20060018904-A1 Combination therapies utilizing benzamide inhibitors of the P2X7 receptor WARNER-LAMBERT COMPANY LLC 2006-01-26 US disclosed
US-6974812-B2 Benzamide inhibitors of the P2X7 Ereceptor PFIZER INC. (US) 2005-12-13 US disclosed
EP-1581232-A1 3-(3,5-DIOXO-4,5-DIHYDRO-3H-(1,2,4)TRIAZIN-2-YL)-BENZAMIDE DERIVATIVES AS P2X7-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES Pfizer Products Inc. (US) 2005-10-05 EP disclosed
US-20040180894-A1 such as 2-chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide; purinergic receptors (P2x7 E); for treatment of interleukin-1 associated disorders (rheumatoid arthritis) PFIZER INC. 2004-09-16 US disclosed
WO-2004058270-A1 3-(3,5-DIOXO-4,5-DIHYDRO-3H-(1,2,4)TRIAZIN-2-YL)-BENZAMIDE DERIVATIVES AS P2X7-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES PFIZER PRODUCTS INC. (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042886-A1 Benzamide Inhibitors of the P2X7 Receptor IL1R1, P2RY1, P2RX1 P2RX7 7/4885
US-20040180894-A1 such as 2-chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide; purinergic receptors (P2x7 E); for treatment of interleukin-1 associated disorders (rheumatoid arthritis) IL1R1, P2RY1, P2RX7 P2RX7 3/4885
US-20060018904-A1 Combination therapies utilizing benzamide inhibitors of the P2X7 receptor CSF3R, CSF1R, IL1R1 P2RX7 72/4885
US-20070281939-A1 Benzamide Inhibitors of The P2X7 Receptor IL1R1, P2RY1, P2RX1 P2RX7 7/4885
US-20060040939-A1 Benzamide inhibitors of the P2X, receptor IL1R1, P2RX1, P2RX3 P2RX7 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.